Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;46(12):e2400072.
doi: 10.1002/bies.202400072. Epub 2024 Jun 25.

iPS cell therapy 2.0: Preparing for next-generation regenerative medicine

Kelvin K Hui  1 , Shinya Yamanaka  1   2   3
Affiliations
Review

iPS cell therapy 2.0: Preparing for next-generation regenerative medicine

Kelvin K Hui et al. Bioessays. 2024 Dec.

Abstract

This year marks the tenth anniversary of the world's first transplantation of tissue generated from induced pluripotent stem cells (iPSCs). There is now a growing number of clinical trials worldwide examining the efficacy and safety of autologous and allogeneic iPSC-derived products for treating various pathologic conditions. As we patiently wait for the results from these and future clinical trials, it is imperative to strategize for the next generation of iPSC-based therapies. This review examines the lessons learned from the development of another advanced cell therapy, chimeric antigen receptor (CAR) T cells, and the possibility of incorporating various new bioengineering technologies in development, from RNA engineering to tissue fabrication, to apply iPSCs not only as a means to achieve personalized medicine but also as designer medical applications.

Keywords: bioengineering; cell therapy; clinical trials; iPS cells; regenerative medicine; transplantation.

PubMed Disclaimer

References

REFERENCES

    1. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861–872. https://doi.org/10.1016/j.cell.2007.11.019
    1. Mandai, M., Kurimoto, Y., & Takahashi, M. (2017). Autologous induced stem‐cell‐derived retinal cells for macular degeneration. New England Journal of Medicine, 377(8), 792–793. https://doi.org/10.1056/nejmc1706274
    1. Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., Hono, A., Fujino, S., Koide, N., Sakai, N., Shibata, Y., Terada, M., Nishida, M., Dohi, H., Nomura, M., … Takahashi, M. (2020). HLA‐matched allogeneic iPS cells‐derived RPE transplantation for macular degeneration. Journal of Clinical Medicine, 9(7), 2217. https://doi.org/10.3390/jcm9072217
    1. Kim, J. Y., Nam, Y., Rim, Y. A., & Ju, J. H. (2022). Review of the current trends in clinical trials involving induced pluripotent stem cells. Stem Cell Reviews and Reports, 18(1), 142–154. https://doi.org/10.1007/s12015‐021‐10262‐3
    1. Kobold, S., Bultjer, N., Stacey, G., Mueller, S. C., Kurtz, A., & Mah, N. (2023). History and current status of clinical studies using human pluripotent stem cells. Stem Cell Reports, 18(8), 1592–1598. https://doi.org/10.1016/j.stemcr.2023.03.005

MeSH terms

Substances

LinkOut - more resources